The Cytokinetics next-generation myosin inhibitor, aficamten, is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30 mg QD. It follows BMS’s mavacamten (acquired from Myokardia in…
Home > aficamten
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.